MAIA

MAIA Biotechnology NYSEAM:MAIA Stock Report

Last Price

US$3.50

Market Cap

US$38.3m

7D

1.7%

1Y

n/a

Updated

27 Nov, 2022

Data

Company Financials +
MAIA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MAIA Stock Overview

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.

MAIA Biotechnology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MAIA Biotechnology
Historical stock prices
Current Share PriceUS$3.50
52 Week HighUS$9.64
52 Week LowUS$3.10
Beta0
1 Month Change0%
3 Month Change-8.14%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-21.53%

Recent News & Updates

Recent updates

Shareholder Returns

MAIAUS BiotechsUS Market
7D1.7%0.4%1.3%
1Yn/a-14.4%-18.5%

Return vs Industry: Insufficient data to determine how MAIA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MAIA performed against the US Market.

Price Volatility

Is MAIA's price volatile compared to industry and market?
MAIA volatility
MAIA Average Weekly Movement10.4%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MAIA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: Insufficient data to determine MAIA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20189Vlad Vitochttps://www.MAIABiotech.com

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc. Fundamentals Summary

How do MAIA Biotechnology's earnings and revenue compare to its market cap?
MAIA fundamental statistics
Market CapUS$38.31m
Earnings (TTM)-US$15.02m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MAIA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$15.02m
Earnings-US$15.02m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.37
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did MAIA perform over the long term?

See historical performance and comparison